1 A systematic review on machine learning approaches in the diagnosis

of rare genetic diseases

- 3 Roman-Naranjo P^{1,2,3}, Parra-Perez AM^{1,2,3,4}, Lopez-Escamez JA^{1,2,3,4}
- 4

2

¹Otology and Neurotology Group CTS495, Department of Genomic Medicine, GENYO

6 - Centre for Genomics and Oncological Research - Pfizer, University of Granada, Junta

- 7 de Andalucía, PTS, Granada, Spain.
- ²Division of Otolaryngology, Department of Surgery, Instituto de Investigación
 Biosanitaria, ibs.GRANADA, Granada, Universidad de Granada, Granada, Spain.
- ³Sensorineural Pathology Programme, Centro de Investigación Biomédica en Red en
- 11 Enfermedades Raras, CIBERER, Madrid, Spain
- ⁴Meniere's Disease Neuroscience Research Program, Faculty of Medicine & Health,
- 13 School of Medical Sciences, The Kolling Institute, University of Sydney, Sydney, New
- 14 South Wales, Australia
- 15
- 16
- 17 All correspondence should be addressed to:
- 18 pablo.roman@genyo.es; jalopezescamez@ugr.es

19 Abstract

Background: The diagnosis of rare genetic diseases is often challenging due to the complexity of the genetic underpinnings of these conditions and the limited availability of diagnostic tools. Machine learning (ML) algorithms have the potential to improve the accuracy and speed of diagnosis by analyzing large amounts of genomic data and identifying complex multiallelic patterns that may be associated with specific diseases. In this systematic review, we aimed to identify the methodological trends and the ML application areas in rare genetic diseases.

Methods: We performed a systematic review of the literature following the PRISMA guidelines to search studies that used ML approaches to enhance the diagnosis of rare genetic diseases. Studies that used DNA-based sequencing data and a variety of ML algorithms were included, summarized, and analyzed using bibliometric methods, visualization tools, and a feature co-occurrence analysis.

32 Findings: Our search identified 22 studies that met the inclusion criteria. We found that 33 exome sequencing was the most frequently used sequencing technology (59%), and rare 34 neoplastic diseases were the most prevalent disease scenario (59%). In rare neoplasms, 35 the most frequent applications of ML models were the differential diagnosis or stratification of patients (38.5%) and the identification of somatic mutations (30.8%). In 36 37 other rare diseases, the most frequent goals were the prioritization of rare variants or genes (55.5%) and the identification of biallelic or digenic inheritance (33.3%). The 38 39 most employed method was the random forest algorithm (54.5%). In addition, the 40 features of the datasets needed for training these algorithms were distinctive depending on the goal pursued, including the mutational load in each gene for the differential 41 diagnosis of patients, or the combination of genotype features and sequence-derived 42 features (such as GC-content) for the identification of somatic mutations. 43

44 Conclusions: ML algorithms based on sequencing data are mainly used for the 45 diagnosis of rare neoplastic diseases, with random forest being the most common 46 approach. We identified key features in the datasets used for training these ML models 47 according to the objective pursued. These features can support the development of 48 future ML models in the diagnosis of rare genetic diseases.

49 Keywords: artificial intelligence, rare diseases, precision medicine, rare variants, DNA-

50 sequencing, genomics

51 **1. Introduction**

Rare diseases (RDs) continue to be a challenge to the healthcare system due to the difficulty of reaching an accurate diagnosis. Although there is no uniform international criteria, RDs are usually defined as those affecting fewer than 4-5 cases out of 10,000 individuals¹. Considering them as a whole, RDs can be regarded as a common event, with 7,241 different RDs (<u>http://www.orphadata.org/data/xml/en_product7.xml</u>, updated on June 14, 2022) with an estimated accumulated prevalence of 3.5–5.9% and affecting more than 400 million people worldwide^{2,3}.

59 Most RDs appear to be caused or modified by genetic factors; up to 80% of them are thought to have a genetic etiology⁴. Our current knowledge on this aspect is limited, 60 61 existing 3,886 RDs (53.7%) linked to, at least, a gene that cause or modify the disease 62 phenotype (http://www.orphadata.org/data/xml/en_product6.xml, updated on 14 Jun $(22)^2$. The improved performance and the price reduction of Next-generation sequencing 63 64 (NGS) technologies in recent years have made them more attractive for clinical applications in RDs, increasing rapidly the number of phenotype-genotype 65 associations⁵. This has resulted in an accurate molecular diagnosis in many patients 66 suffering from monogenic RDs, which has occasionally led to personalized treatments 67 and improved disease management. Nevertheless, other patients with more complex 68 69 disorders receive an inconclusive genetic diagnosis, placing the diagnostic yield of DNA-based NGS technologies in most studies at 40-50%^{6,7}. This is mainly caused by 70 the absence of pathogenic or likely pathogenic variants in known disease-causing genes, 71 72 finding instead variants of unknown significance (VUS) or variants in novel genes not previously associated with the disease. 73

In this scenario of rare and complex genetic disorders where a diagnosis is not reached or a prognosis is not accurate enough, more sophisticated methods should be applied to analyze large-scale genomic data. The use of artificial intelligence (AI) and, particularly, machine learning (ML) algorithms has raised great interest in recent years due to its potential to uncover complex patterns in genomic data⁸. These ML algorithms have shown the capacity to learn from and act on large, heterogeneous datasets to extract new biological insights, improving the accuracy of the diagnosis of RDs⁹⁻¹².

Compared to previous reviews in the field of ML and RDs, such as Schaefer et al.9 or 81 Brasil *et al.*¹³, in this systematic review we used a different approach, investigating the 82 83 role of AI/ML algorithms in the diagnosis and prognosis of RDs using genomic data. 84 The range of options when it comes to choosing a learning algorithm or a DNA-based 85 NGS technique to address RDs is highly variable. On the one hand, ML methods are 86 usually divided into two main categories: supervised and unsupervised learning. 87 Supervised ML algorithms require labeled data to solve mainly regression and 88 classification tasks, whereas unsupervised ML algorithms address classification tasks 89 based on unlabeled data by seeking common patterns. The review from Libbrecht et al. describes these algorithms in more detail and provides examples applied to genomic 90 data¹⁴. On the other hand, regarding NGS techniques, there are mainly two strategies: a) 91 92 to sequence the entirety of the DNA sequence (whole genome sequencing, WGS), or b) 93 to just sequence some regions of the DNA, such as coding regions (exome sequencing, 94 ES), or certain disease-causing genes (gene panel). Nevertheless, the raw data generated 95 in these experiments can be processed in many ways, with different workflows 96 depending on the aim of the study.

97 This systematic review presents a thorough overview of the existing evidence on the98 application of AI/ML algorithms to the diagnosis of RDs using DNA-based sequencing

99	data. We conducted a comprehensive search of the literature and included studies that
100	used a variety of ML approaches and sequencing data sources in different research
101	settings. Our analysis focused on the evaluation of trends in the field, the ability of these
102	approaches to identify genetic variations associated with RDs, and the potential of
103	AI/ML to improve their diagnosis.

2. Methods

105 **2.1. Systematic literature search and data sources**

We performed a literature search using PubMed, Web of Science, and Scopus to identify relevant publications on the use of AI/ML for the diagnosis and prognosis of RDs using genomic data. We also used citation and hand searching to ensure that potentially relevant studies were retrieved. The Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines were followed to design and perform this systematic review¹⁵, and its protocol was registered in PROSPERO (registration number CRD42022360247).

113 A search in the selected databases using the search terms 'rare AND ("artificial 114 intelligence" OR "machine learning" OR "deep learning") AND ((exome OR genome 115 OR panel) AND sequencing)' and considering publications from 2012 onward resulted 116 in 296 abstracts. The citation and hand searching resulted in 10 additional records. The 117 date of the last search was September 29, 2022.

The list of abstracts was screened for inclusion using the following inclusion criteria: (i) 118 119 an application of AI/ML methods; (ii) a diagnostic or prognosis application using a DNA-based NGS technique (panel, exome, or genome sequencing); and (iii) an 120 121 application to a RD within the orpha.net database. Non-English articles, review articles, duplicate records, and studies not relevant to any RD or AI/ML were excluded. To 122 narrow our focus to clinical applications, we excluded animal studies as well as 123 publications that only reported methodological aspects of AI/ML without presenting 124 125 clinical data from the study population. For all articles considered relevant, the full text 126 was reviewed using the same screening procedure as in the first stage.

127 **2.2. Data extraction**

All the selected articles were evaluated to gather data on five main aspects: i) study 128 characteristics and study population (subjects included, RDs studied, study design, use 129 of secondary data), ii) characteristics of the applied AI/ML techniques (selected ML 130 model, programming languages used, input data, associated features, feature selection 131 methods, model evaluation), iii) information about the DNA-based NGS technology 132 used (type, sample collected, DNA sequencing kit, sequencing platform, read length, 133 134 mean coverage), iv) the variant discovery approach (alignment method, used SNV/Indel/CNVs callers, variant annotation software, variant filtering criteria), and v) 135 136 authors (number of authors and institutions involved, authors' countries) and journal 137 details (name, category, journal impact factor, journal citation indicator).

138 **2.3. Data analysis**

The data collected from selected articles were summarized and analyzed using a variety of approaches. Journal Impact Factor (JIF) scores were obtained from the Journal Citation Report (JCR) database. Bibliometric networks, including data from authors and abstracts, were constructed and visualized using VOSviewer¹⁶. Similarly, full-text articles were analyzed using WordStat 9.0 (Provalis Research, Montreal, Quebec, Canada) to extract main topics and keywords.

Selected articles were divided into "rare neoplastic diseases" and "other rare diseases" to enable comparisons. AI/ML models were categorized into three categories: supervised, unsupervised, and deep learning models. Input variables that the model uses to make predictions (features) were classified in 1) "clinical features", which include information about patients' clinical characteristics; 2) "phenotype-related features", including data about the association between genes and phenotypes (e.g., Human

151 Phenotype Ontology); 3) "read alignment features", which include the properties related to read mapping and sequencing quality; 4) "genotype-related features", including 152 153 details of variants found in patients (e.g., variant allele frequency, count of variants in a certain gene, length of indel); 5) "sequence region and structural features", including 154 information about the region where the variant is located (e.g., gene size, GC content); 155 6) "network features", which include details about the pathways in which a particular 156 neighbors); 157 gene is involved (e.g., number of pathway, network 7) "evolutionary/pathogenicity features", which include pathogenicity and evolutionary 158 159 conservation scores of variants (e.g., CADD, PolyPhen-2); 8) "gene expression 160 features", including data on gene expression; 9) "tissue-specific features", including features which are specific for certain types of tissues; and 10) "disease-specific 161 features", including features which are specific for certain types of diseases. The co-162 occurrence of these features in the datasets used for training AI/ML models was 163 examined and plotted using UpSetR¹⁷. 164

165 **3. Results**

166 **3.1. Included studies**

The literature search in databases identified 494 studies, with 296 remaining after removing duplicates (**Supplementary Table 1**). Among them, 93 studies were selected for full-text review, and 14 were included in the final analysis. In addition, 11 studies were identified through hand and citation searching. After screening, 8 further studies met the selection criteria of this systematic review. Thus, 22 studies were included in the final analysis (**Supplementary Table 2**). **Figure 1** shows the PRISMA flow diagram for article selection, including the reasons for excluding records.

3.2. Temporal trends and bibliometrics

175 To assess the temporal trends in the use of AI/ML methods for the diagnosis and prognosis of RDs using sequencing data, meta-data from included articles was retrieved 176 (Supplementary Table 3). In recent years, we noticed a relative rise in the number of 177 studies that address this challenge using AI/ML (Figure 2A). Most of these articles 178 179 were published in journals belonging to the first quartile (90.9%) and within the "Genetics & Hereditary" JCR category (31.8%) (Supplementary Figure 1). It should 180 be noted that the count for 2022 is based on studies published up to September 29, 181 2022. 182

A total of 318 authors contributed to the selected articles. The bibliometric analysis showed a low level of collaboration between authors of different articles, creating 19 clusters where only 3 authors participated in 2 or more articles (**Supplementary Figure 2A**). The term co-occurrence analysis of abstracts found 100 relevant terms divided into 3 clusters that summarize the main topics of this research field. These clusters group together terms mainly associated with genetics (cluster 1), cancer (cluster 2), and methodology terms (cluster 3) (**Figure 2B**). The most frequently occurring terms in

these abstracts were "genetics" (18 occurrences), "machine learning" (15 occurrences) and "whole-exome sequencing" (10 occurrences). These key terms were also among the most frequently used terms in the analysis of full-text articles, where terms such as "random forest" (59.1% of studies), "somatic mutations" (54.5% of studies), or "rare variants" (54.5% of studies) were also in a significant proportion of studies (Supplementary Figure 2B).

3.3. Application areas for AI/ML techniques

197 The most common disease scenario was rare neoplastic diseases (59%). The remaining 198 studies investigated different kinds of RDs, such as developmental, neurological, or 199 circulatory diseases (Figure 3A). Exome sequencing was the most used NGS method in 200 both rare neoplastic diseases (61.5%) and other RDs (55.5%) (Figure 3B). Of note, 201 63.6% (14/22) of the studies employed sequencing data stored in external databases, 202 primarily The Cancer Genome Atlas (TCGA), but also the Myocardial Genetics 203 Consortium (MIGEN), or the Undiagnosed Diseases Network (UDN). These studies 204 showed larger sample sizes than those using their own cohorts (Supplementary Figure 205 3), but they also showed higher intra-method variability, as seen by the mixed sample 206 processing methods they employed (Supplementary Figure 4). Supplementary Table 207 **4** summarizes the NGS-related and sequencing data processing methods in detail.

Supervised machine learning methods were chosen in 86.3% of the studies, with Random Forest (RF) being the most employed algorithm within this group (54.5%) (Figure 3C). One study discarded the genetic features after the feature selection process, and three studies did not describe the selected features in detail, one of which was due to a commercial interest (Supplementary Table 5).

3.4. AI/ML in the study of rare genetic diseases

The objectives of AI/ML approaches in the different studies were investigated. It was found that the primary goal of using AI/ML in rare neoplastic diseases was the differential diagnosis of patients (5/13), followed by the identification of somatic mutations when a matched normal tissue was not available (4/13). In contrast, the major goals in other RDs were to prioritize variants and candidate genes (5/9) and to identify biallelic or digenic inheritance (3/9). To date, the use of AI/ML for the differential diagnosis of patients with non-neoplastic diseases is uncommon (1/9) (**Figure 4A**).

221 Looking at the types of instances (labels) and features (attributes) of datasets used for 222 training these AI/ML models, we found that they were distinctive and different 223 depending on the goal pursued (**Table 1** and **Figure 4B**). For the differential diagnosis of patients, most datasets included only features related to the genotype of patients. 224 225 These features primarily contained mutational load data for each gene or genomic 226 window using collapsing methods. Models trained to predict the prognosis of RDs 227 included clinical features (e.g., sex, age, exposure to certain substances) in addition to 228 genotype features. The four AI/ML models aimed at finding possible pathogenic 229 combinations of genes (digenic) or variants (biallelic) shared the usage of features related to biological networks or pathways (e.g., the associated pathway of each gene in 230 231 KEGG or Reactome, network neighbors). Datasets focused on training models for variant or gene prioritization were distinguished by using features linked to predictors 232 233 of variant pathogenicity at protein level and conservation across the genome of different 234 species. Finally, for the identification of somatic mutations without a matched normal 235 sample, the AI/ML models combined genotype features (e.g., variant allele frequency) 236 with characteristics of the genome region where the variant is located (e.g., GC-content) 237 or sequencing and mapping quality scores (e.g., coverage). Supplementary Table 6 contains further information regarding the types of features mentioned above. 238

239 **3.5. Data and code access for reproducibility**

240	When it comes to studies that define ML models, reproducibility is a key factor. Of the
241	selected articles, 16 studies (72.7%) provided access to the data used during the
242	analysis; 3 studies did so only upon data request; and 3 did not explicitly declare in the
243	text that data were available, one of which was due to commercial confidentiality. In
244	terms of the code of AI/ML models, 16 studies (72.7%) had made it publicly available.
245	With respect to the variant discovery approaches, all studies specified the software used
246	for sequence alignment; 21 studies (95.5%) included information about the variant
247	calling step; 17 studies (77.3%) did not mention the use of copy number variations
248	(CNVs) during the analysis, and 3 studies did not state how the variants were annotated.
249	Supplementary Table 7 summarizes data availability and reproducibility information.

4. Discussion

AI/ML involve the use of algorithms to process and gain insights from data with the aim of making predictions or decisions that can be applied to a wide range of fields, including healthcare and genetics. In this systematic review, we have evaluated the latest developments in AI/ML when it comes to rare genetic conditions and examined the ways in which the use of DNA sequencing data can improve their diagnosis. In addition, we have identified some challenges and opportunities for future research in this area.

4.1. Exome sequencing and rare neoplastic diseases as main topics

Although to a lesser extent than in other types of diagnostic methods, such as medical 259 imaging, AI/ML are increasingly being used in the field of RDs^{9,18,19}. This trend was 260 also found when focusing only on those studies that use DNA sequencing data to 261 improve the diagnostic process. Through the bibliometric study carried out in this 262 263 review, and the subsequent manual analyses, we found that exome sequencing was the 264 most prevalent sequencing approach in the field, and that rare neoplastic diseases were 265 the most prevalent clinical scenario. Exome sequencing continues to be a good starting 266 point for the genetic diagnosis of RDs, as it provides a cost-effective and efficient way to identify disease-causing variants²⁰. However, depending on the specific rare disease 267 268 context, genome sequencing may be necessary to provide a complete diagnosis, including the analysis of non-coding variations, CNVs, or chromosomal 269 rearrangements^{21,22}. 270

Rare neoplastic diseases generally have a worse diagnosis and higher funding
opportunities than other RDs, making them the type of rare disease in which AI/ML are
used the most^{19,23}. This is also due to the existence of public databases such as TCGA,

274 which allow researchers to access a large amount of genomic data and use AI/ML techniques to identify patterns and make predictions²⁴. When we analyzed the data on 275 276 which these AI/ML models were trained, we saw that many of them (63.6%) were based on sequencing data from external sources, such as TCGA. These studies showed larger 277 278 sample sizes, but also a greater diversity in sequencing technology characteristics such as read depth, different length of reads or different sequencing kits and platforms. 279 280 Mixing sequencing data from different technologies, qualities, and batches can have 281 several biases that can influence the variant calling results, affecting in turn the results 282 of downstream analyses, and making difficult to draw accurate conclusions from the data²⁵. The precision when taking clinical decisions must be maximized, so these 283 studies must have control over these factors²⁶. Different studies have shown how to 284 approach this process 25,27 . 285

4.2. AI/ML algorithms and feature selection in genetic studies

287 Most of the methods utilized in the selected studies fall into the category of supervised learning (86.7%), with RF being the most common algorithm among them (73.7%). RF 288 289 algorithm offers a combination of properties that makes it one of the most widely used and suitable algorithms for the study of genetic variants^{28,29}. RF combines multiple 290 291 decision trees (forest) that can handle high-dimensional data, capturing interactions and complex relationships between features by creating random subsets of both, data and 292 293 features, at each tree. In addition, RF also allows to compute feature importances, which can be used to identify the most relevant features for the prediction task, providing 294 interpretable models³⁰. All this makes RF well suited for complex genetic problems and 295 296 explains its popularity among the genetic studies.

297 The structure of the dataset is a fundamental and key aspect of any AI/ML model, as it is the data that the model uses to learn and make predictions. The processes of feature 298 299 selection and feature engineering can have a substantial effect on the performance of the model; hence, it is essential that the final features possess relevance to the problem at 300 hand³¹. In this systematic review, we have identified the features used by each of the 301 302 selected studies and found that these features were specific to each of the objectives 303 pursued. This insight can be valuable in understanding the current state of research in 304 the field, and it can serve as a starting point for creating new datasets in future studies.

305 The results suggested that collapsing or burden methods seem to be crucial for setting 306 up the features of datasets used to train models for the stratification or differential diagnosis of patients. These methods divide the genome into portions (bins or genes) 307 308 and summarize the information contained in these segments into a burden value, which can be calculated in different ways^{32,33}. This approach has shown its usefulness in 309 finding candidate genes in different complex RDs with both genome and exome 310 sequencing data^{34–36}. Thus, applied to AI/ML tasks, this process helps to decrease the 311 312 dimensionality of datasets based on genetic variants by grouping them into one value per gene or bin, which helps to reduce the curse of dimensionality and improve 313 interpretability³⁷. 314

On the other hand, models focused on predicting patient prognosis integrate clinical and genomic data to obtain a more complete picture of the patient and assess the risk of disease progression. Previous studies, particularly in cancer, have shown how this integration of data provides a more comprehensive and accurate assessment of patient outcome ^{38,39}. Alternatively, models aimed at predicting possible pathogenic combinations of genes use features that summarize the association of these genes with the biological pathways in which they participate. The use of these features is supported

by the fact that digenic diseases are usually caused by variants in genes that are
 functionally related and have a common pathway^{40,41}.

324 **4.3.** Future challenges

325 From the results of this review, we identified some challenges that need to be addressed 326 in future studies. When we analyzed the type of genomic data used to train the AI/ML models reviewed, we realized that most of them (77.3%) were based exclusively on 327 328 single nucleotide variants or short indels, not including the analysis of CNVs. CNVs are 329 a significant source of genetic diversity in humans that has remained understudied due to the difficulty of detection. However, today there are different algorithms for CNV 330 331 detection that simplify the task considerably, as well as guidelines that help us to interpret them^{42,43}. This allows the possibility of evaluating its effect on the 332 pathogenesis and outcome of RD. On the other hand, when we examine the goals 333 pursued in the analysis of neoplastic RDs, we can see that the differential diagnosis or 334 335 stratification of patients stands out above the other objectives. This is totally different in other RDs, where, in fact, this objective is the least pursued of the 3 objectives 336 337 identified, and, therefore, a field where the contribution of genetic variation to the phenotype is not well understood. The use of AI/ML algorithms on rare disease 338 339 sequencing data can support the identification of novel genetic interactions, uncovering 340 patterns and relationships that may not be immediately apparent and providing a better 341 understanding of the regulatory mechanisms mediated by these variants in the phenotype. The use of unsupervised methods would be a possible first approach to 342 achieve the objective of identifying clusters of patients according to their genetic 343 background⁴⁴. 344

345 **4.4.** Limitations

Our review is limited by the design of the systematic search and the exclusion of purely 346 methodological articles, focusing only on those studies with clinical applications. 347 348 Because of the limited number of studies available on the topic, and although it has been studied, articles have not been discarded because of the quality of the journal in 349 350 which they were published (i.e., JIF), and this may have influenced, in some way, the 351 results of this review. In addition, to reduce variability in study methodology and 352 facilitate the analysis, we have only focused on those studies using DNA-based sequencing, not including other NGS methodologies such as RNA-seq, which are 353 widely used in conjunction with AI/ML methodologies⁴⁵⁻⁴⁷. 354

355

5. Conclusions

356 We have conducted a systematic review of ML algorithms to the diagnosis of RDs 357 using DNA-based sequencing data, providing an overview of the current state of the 358 field and the potential of these methods to improve diagnostic accuracy. Exome sequencing is the most widely used sequencing technology and rare neoplastic diseases 359 360 are the most common disease scenario. On the other hand, the goals of AI/ML algorithms in RDs using sequencing data are broad, ranging from patient stratification 361 to the identification of possible pathogenic combinations of variants. However, we 362 found common patterns in these goals when configuring the datasets with which these 363 364 models are trained, identifying key features for each of the objectives. Finally, we identified possible future challenges, such as the use of CNV to train the AI/ML 365 366 models, or the application of AI/ML for the stratification of patients with non-neoplastic RDs. Thus, this systematic review can be used as a reference for further studies, 367 supporting the development of future ML models in the diagnosis of rare genetic 368 369 diseases

6. Fundings

371 JALE has received funds from Instituto de Salud Carlos III (Grant# PI20-1126), 372 CIBERER (Grant# PIT21_GCV21), Andalusian University, Research and Innovation Department (PY20-00303, EPIMEN), Andalusian Health Department (Grant# PI027-373 374 2020), Asociación Síndrome de Meniere España (ASMES) and Meniere's Society, UK. PRNV is supported by PY20-00303 Grant (EPIMEN). AMPP is a PhD student in the 375 376 Biomedicine Program at Universidad de Granada and his salary was supported by 377 Andalusian University, Research and Innovation Department (Grant# PREDOC2021/00343). 378

7. Declaration of Competing Interest

The authors declare that they have no competing interests. The research was conducted independent of any commercial or financial relationships that could be construed as a potential conflict of interest.

383 **8. References**

384 385 386	1.	Richter T, Nestler-Parr S, Babela R, et al. Rare Disease Terminology and Definitions—A Systematic Global Review: Report of the ISPOR Rare Disease Special Interest Group. <i>Value</i> <i>Health</i> . 2015;18(6):906-914. doi:10.1016/j.jval.2015.05.008
387 388	2.	Orphadata: Free access data from Orphanet. © INSERM 1999. Available on http://www.orphadata.org. Data version (XML data version).
389 390 391	3.	Nguengang Wakap S, Lambert DM, Olry A, et al. Estimating cumulative point prevalence of rare diseases: analysis of the Orphanet database. <i>Eur J Hum Genet</i> . 2020;28(2):165-173. doi:10.1038/s41431-019-0508-0
392 393 394	4.	100,000 Genomes Project Pilot Investigators, Smedley D, Smith KR, et al. 100,000 Genomes Pilot on Rare-Disease Diagnosis in Health Care - Preliminary Report. <i>N Engl J Med</i> . 2021;385(20):1868-1880. doi:10.1056/NEJMoa2035790
395 396	5.	Wise AL, Manolio TA, Mensah GA, et al. Genomic Medicine for Undiagnosed Diseases. Lancet Lond Engl. 2019;394(10197):533-540. doi:10.1016/S0140-6736(19)31274-7
397 398 399	6.	Vinkšel M, Writzl K, Maver A, Peterlin B. Improving diagnostics of rare genetic diseases with NGS approaches. <i>J Community Genet</i> . 2021;12(2):247-256. doi:10.1007/s12687-020- 00500-5
400 401 402	7.	Dai P, Honda A, Ewans L, et al. Recommendations for next generation sequencing data reanalysis of unsolved cases with suspected Mendelian disorders: A systematic review and meta-analysis. <i>Genet Med</i> . Published online May 14, 2022. doi:10.1016/j.gim.2022.04.021
403 404	8.	Routhier E, Mozziconacci J. Genomics enters the deep learning era. <i>PeerJ</i> . 2022;10:e13613. doi:10.7717/peerj.13613
405 406 407	9.	Schaefer J, Lehne M, Schepers J, Prasser F, Thun S. The use of machine learning in rare diseases: a scoping review. <i>Orphanet J Rare Dis</i> . 2020;15(1):145. doi:10.1186/s13023-020- 01424-6
408 409 410 411	10.	Setty ST, Scott-Boyer MP, Cuppens T, Droit A. New Developments and Possibilities in Reanalysis and Reinterpretation of Whole Exome Sequencing Datasets for Unsolved Rare Diseases Using Machine Learning Approaches. <i>Int J Mol Sci</i> . 2022;23(12):6792. doi:10.3390/ijms23126792
412 413 414	11.	Cohen ASA, Farrow EG, Abdelmoity AT, et al. Genomic answers for children: Dynamic analyses of >1000 pediatric rare disease genomes. <i>Genet Med Off J Am Coll Med Genet</i> . 2022;24(6):1336-1348. doi:10.1016/j.gim.2022.02.007
415 416 417	12.	Okazaki A, Ott J. Machine learning approaches to explore digenic inheritance. <i>Trends Genet TIG</i> . Published online May 14, 2022:S0168-9525(22)00105-6. doi:10.1016/j.tig.2022.04.009
418 419 420	13.	Brasil S, Pascoal C, Francisco R, dos Reis Ferreira V, A. Videira P, Valadão G. Artificial Intelligence (AI) in Rare Diseases: Is the Future Brighter? <i>Genes</i> . 2019;10(12):978. doi:10.3390/genes10120978

421 422	14.	Libbrecht MW, Noble WS. Machine learning applications in genetics and genomics. <i>Nat Rev Genet</i> . 2015;16(6):321-332. doi:10.1038/nrg3920
423 424 425	15.	Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: An updated guideline for reporting systematic reviews. <i>PLOS Med</i> . 2021;18(3):e1003583. doi:10.1371/journal.pmed.1003583
426 427	16.	van Eck NJ, Waltman L. Software survey: VOSviewer, a computer program for bibliometric mapping. <i>Scientometrics</i> . 2010;84(2):523-538. doi:10.1007/s11192-009-0146-3
428 429 430	17.	Lex A, Gehlenborg N, Strobelt H, Vuillemot R, Pfister H. UpSet: Visualization of Intersecting Sets. <i>IEEE Trans Vis Comput Graph</i> . 2014;20(12):1983-1992. doi:10.1109/TVCG.2014.2346248
431 432 433	18.	Oren O, Gersh BJ, Bhatt DL. Artificial intelligence in medical imaging: switching from radiographic pathological data to clinically meaningful endpoints. <i>Lancet Digit Health</i> . 2020;2(9):e486-e488. doi:10.1016/S2589-7500(20)30160-6
434 435	19.	Lee J, Liu C, Kim J, et al. Deep learning for rare disease: A scoping review. <i>J Biomed Inform</i> . 2022;135:104227. doi:10.1016/j.jbi.2022.104227
436 437 438	20.	Klau J, Abou Jamra R, Radtke M, et al. Exome first approach to reduce diagnostic costs and time – retrospective analysis of 111 individuals with rare neurodevelopmental disorders. <i>Eur J Hum Genet</i> . 2022;30(1):117-125. doi:10.1038/s41431-021-00981-z
439 440 441	21.	Marwaha S, Knowles JW, Ashley EA. A guide for the diagnosis of rare and undiagnosed disease: beyond the exome. <i>Genome Med</i> . 2022;14(1):23. doi:10.1186/s13073-022-01026-w
442 443 444	22.	Souche E, Beltran S, Brosens E, et al. Recommendations for whole genome sequencing in diagnostics for rare diseases. <i>Eur J Hum Genet</i> . 2022;30(9):1017-1021. doi:10.1038/s41431-022-01113-x
445 446 447	23.	Dlamini Z, Francies FZ, Hull R, Marima R. Artificial intelligence (AI) and big data in cancer and precision oncology. <i>Comput Struct Biotechnol J</i> . 2020;18:2300-2311. doi:10.1016/j.csbj.2020.08.019
448 449	24.	Weinstein JN, Collisson EA, Mills GB, et al. The Cancer Genome Atlas Pan-Cancer Analysis Project. <i>Nat Genet.</i> 2013;45(10):1113-1120. doi:10.1038/ng.2764
450 451 452	25.	De-Kayne R, Frei D, Greenway R, Mendes SL, Retel C, Feulner PGD. Sequencing platform shifts provide opportunities but pose challenges for combining genomic data sets. <i>Mol Ecol Resour</i> . 2021;21(3):653-660. doi:10.1111/1755-0998.13309
453 454	26.	Goldfeder RL, Priest JR, Zook JM, et al. Medical implications of technical accuracy in genome sequencing. <i>Genome Med</i> . 2016;8(1):24. doi:10.1186/s13073-016-0269-0
455 456 457	27.	Ellrott K, Bailey MH, Saksena G, et al. Scalable Open Science Approach for Mutation Calling of Tumor Exomes Using Multiple Genomic Pipelines. <i>Cell Syst</i> . 2018;6(3):271-281.e7. doi:10.1016/j.cels.2018.03.002
458 459	28.	Goldstein BA, Polley EC, Briggs FBS. Random Forests for Genetic Association Studies. <i>Stat</i> Appl Genet Mol Biol. 2011;10(1):32. doi:10.2202/1544-6115.1691

460 461	29.	Chen X, Ishwaran H. Random Forests for Genomic Data Analysis. <i>Genomics</i> . 2012;99(6):323-329. doi:10.1016/j.ygeno.2012.04.003
462	30.	Breiman L. Random Forests. Mach Learn. 2001;45(1):5-32. doi:10.1023/A:1010933404324
463 464 465 466	31.	Pudjihartono N, Fadason T, Kempa-Liehr AW, O'Sullivan JM. A Review of Feature Selection Methods for Machine Learning-Based Disease Risk Prediction. <i>Front Bioinforma</i> . 2022;2. Accessed January 21, 2023. https://www.frontiersin.org/articles/10.3389/fbinf.2022.927312
467 468 469 470	32.	Dering C, König IR, Ramsey LB, Relling MV, Yang W, Ziegler A. A comprehensive evaluation of collapsing methods using simulated and real data: excellent annotation of functionality and large sample sizes required. <i>Front Genet</i> . 2014;5. Accessed January 21, 2023. https://www.frontiersin.org/articles/10.3389/fgene.2014.00323
471 472	33.	Nicolae DL. Association Tests for Rare Variants. <i>Annu Rev Genomics Hum Genet.</i> 2016;17(1):117-130. doi:10.1146/annurev-genom-083115-022609
473 474 475	34.	Roman-Naranjo P, Gallego-Martinez A, Soto-Varela A, et al. Burden of Rare Variants in the OTOG Gene in Familial Meniere's Disease. <i>Ear Hear</i> . 2020;41(6):1598-1605. doi:10.1097/AUD.000000000000878
476 477 478	35.	Dilliott AA, Abdelhady A, Sunderland KM, et al. Contribution of rare variant associations to neurodegenerative disease presentation. <i>NPJ Genomic Med</i> . 2021;6:80. doi:10.1038/s41525-021-00243-3
479 480 481	36.	Lin J, Li C, Cui Y, et al. Rare variants in IMPDH2 cause autosomal dominant dystonia in Chinese population. <i>J Neurol</i> . Published online January 17, 2023. doi:10.1007/s00415-023- 11564-x
482 483	37.	Altman N, Krzywinski M. The curse(s) of dimensionality. <i>Nat Methods</i> . 2018;15(6):399-400. doi:10.1038/s41592-018-0019-x
484 485 486	38.	Lobato-Delgado B, Priego-Torres B, Sanchez-Morillo D. Combining Molecular, Imaging, and Clinical Data Analysis for Predicting Cancer Prognosis. <i>Cancers</i> . 2022;14(13):3215. doi:10.3390/cancers14133215
487 488 489	39.	Gonzalez-Bosquet J, Gabrilovich S, McDonald ME, et al. Integration of Genomic and Clinical Retrospective Data to Predict Endometrioid Endometrial Cancer Recurrence. <i>Int J Mol Sci.</i> 2022;23(24):16014. doi:10.3390/ijms232416014
490 491	40.	Gazzo A, Raimondi D, Daneels D, et al. Understanding mutational effects in digenic diseases. <i>Nucleic Acids Res</i> . 2017;45(15):e140. doi:10.1093/nar/gkx557
492 493	41.	Schäffer AA. Digenic inheritance in medical genetics. <i>J Med Genet</i> . 2013;50(10):641-652. doi:10.1136/jmedgenet-2013-101713
494 495 496 497	42.	Riggs ER, Andersen EF, Cherry AM, et al. Technical standards for the interpretation and reporting of constitutional copy-number variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics (ACMG) and the Clinical Genome Resource (ClinGen). <i>Genet Med</i> . 2020;22(2):245-257. doi:10.1038/s41436-019-0686-8

498 499	43.	Gordeeva V, Sharova E, Arapidi G. Progress in Methods for Copy Number Variation Profiling. Int J Mol Sci. 2022;23(4):2143. doi:10.3390/ijms23042143
500 501	44.	Basile AO, Ritchie MD. Informatics and Machine Learning to Define the Phenotype. <i>Expert Rev Mol Diagn</i> . 2018;18(3):219-226. doi:10.1080/14737159.2018.1439380
502 503 504	45.	Wang L, Xi Y, Sung S, Qiao H. RNA-seq assistant: machine learning based methods to identify more transcriptional regulated genes. <i>BMC Genomics</i> . 2018;19(1):546. doi:10.1186/s12864-018-4932-2
505 506 507	46.	Gunavathi C, Sivasubramanian K, Keerthika P, Paramasivam C. A review on convolutional neural network based deep learning methods in gene expression data for disease diagnosis. <i>Mater Today Proc</i> . 2021;45:2282-2285. doi:10.1016/j.matpr.2020.10.263
508 509 510	47.	Figgett WA, Monaghan K, Ng M, et al. Machine learning applied to whole-blood RNA- sequencing data uncovers distinct subsets of patients with systemic lupus erythematosus. <i>Clin Transl Immunol</i> . 2019;8(12):e01093. doi:10.1002/cti2.1093
511 512 513	48.	Parida L, Haferlach C, Rhrissorrakrai K, et al. Dark-matter matters: Discriminating subtle blood cancers using the darkest DNA. <i>PLoS Comput Biol</i> . 2019;15(8):e1007332. doi:10.1371/journal.pcbi.1007332
514 515 516	49.	Parvandeh S, Donehower LA, Panagiotis K, et al. EPIMUTESTR: a nearest neighbor machine learning approach to predict cancer driver genes from the evolutionary action of coding variants. <i>Nucleic Acids Res</i> . 2022;50(12):e70. doi:10.1093/nar/gkac215
517 518 519	50.	Peneder P, Stütz AM, Surdez D, et al. Multimodal analysis of cell-free DNA whole-genome sequencing for pediatric cancers with low mutational burden. <i>Nat Commun</i> . 2021;12(1):3230. doi:10.1038/s41467-021-23445-w
520 521 522	51.	Li Y, Luo Y. Performance-weighted-voting model: An ensemble machine learning method for cancer type classification using whole-exome sequencing mutation. <i>Quant Biol Beijing China</i> . 2020;8(4):347-358. doi:10.1007/s40484-020-0226-1
523 524 525	52.	Aguiar-Pulido V, Wolujewicz P, Martinez-Fundichely A, et al. Systems biology analysis of human genomes points to key pathways conferring spina bifida risk. <i>Proc Natl Acad Sci U S</i> A. 2021;118(51):e2106844118. doi:10.1073/pnas.2106844118
526 527 528	53.	Chaix MA, Parmar N, Kinnear C, et al. Machine Learning Identifies Clinical and Genetic Factors Associated With Anthracycline Cardiotoxicity in Pediatric Cancer Survivors. <i>JACC</i> <i>CardioOncology</i> . 2020;2(5):690-706. doi:10.1016/j.jaccao.2020.11.004
529 530 531 532	54.	Zauderer MG, Martin A, Egger J, et al. The use of a next-generation sequencing-derived machine-learning risk-prediction model (OncoCast-MPM) for malignant pleural mesothelioma: a retrospective study. <i>Lancet Digit Health</i> . 2021;3(9):e565-e576. doi:10.1016/S2589-7500(21)00104-7
533 534 535	55.	Carter H, Douville C, Stenson PD, Cooper DN, Karchin R. Identifying Mendelian disease genes with the variant effect scoring tool. <i>BMC Genomics</i> . 2013;14 Suppl 3:S3. doi:10.1186/1471-2164-14-S3-S3

536 537 538	56.	Vitsios D, Petrovski S. Mantis-ml: Disease-Agnostic Gene Prioritization from High- Throughput Genomic Screens by Stochastic Semi-supervised Learning. <i>Am J Hum Genet</i> . 2020;106(5):659-678. doi:10.1016/j.ajhg.2020.03.012
539 540	57.	Majithia AR, Tsuda B, Agostini M, et al. Prospective functional classification of all possible missense variants in PPARG. <i>Nat Genet</i> . 2016;48(12):1570-1575. doi:10.1038/ng.3700
541 542 543	58.	Carss KJ, Baranowska AA, Armisen J, et al. Spontaneous Coronary Artery Dissection: Insights on Rare Genetic Variation From Genome Sequencing. <i>Circ Genomic Precis Med</i> . 2020;13(6):e003030. doi:10.1161/CIRCGEN.120.003030
544 545 546	59.	Davis NA, Lareau CA, White BC, et al. Encore: Genetic Association Interaction Network centrality pipeline and application to SLE exome data. <i>Genet Epidemiol</i> . 2013;37(6):614-621. doi:10.1002/gepi.21739
547 548 549	60.	Mukherjee S, Cogan JD, Newman JH, et al. Identifying digenic disease genes via machine learning in the Undiagnosed Diseases Network. <i>Am J Hum Genet</i> . 2021;108(10):1946-1963. doi:10.1016/j.ajhg.2021.08.010
550 551 552	61.	Laan M, Kasak L, Timinskas K, et al. NR5A1 c.991-1G > C splice-site variant causes familial 46,XY partial gonadal dysgenesis with incomplete penetrance. <i>Clin Endocrinol (Oxf)</i> . 2021;94(4):656-666. doi:10.1111/cen.14381
553 554 555	62.	Ainscough BJ, Barnell EK, Ronning P, et al. A deep learning approach to automate refinement of somatic variant calling from cancer sequencing data. <i>Nat Genet</i> . 2018;50(12):1735-1743. doi:10.1038/s41588-018-0257-y
556 557	63.	Wood DE, White JR, Georgiadis A, et al. A machine learning approach for somatic mutation discovery. <i>Sci Transl Med</i> . 2018;10(457):eaar7939. doi:10.1126/scitranslmed.aar7939
558 559 560	64.	Kalatskaya I, Trinh QM, Spears M, McPherson JD, Bartlett JMS, Stein L. ISOWN: accurate somatic mutation identification in the absence of normal tissue controls. <i>Genome Med</i> . 2017;9(1):59. doi:10.1186/s13073-017-0446-9

561

562 Figures

563	Figure 1: PRISMA flow diagram for the identification, screening and selection of
564	genetic studies using AI/ML for the diagnosis of rare diseases.
565	Figure 2: Visualization of temporal trends and bibliometrics. Panel A) shows the
566	selected studies distributed per year and divided into deciles (D) according to journal
567	impact factors (JIF). Panel B) displays a keyword co-occurrence network using abstracts
568	of selected studies.
569	Figure 3: Methods and areas of application. Panel A) displays the distribution of rare
570	disease identified in selected studies. Panel B) shows the next-generation sequencing
571	(NGS) methods used in studies targeting rare neoplastic diseases and other rare
572	diseases. Panel C) summarizes the types of machine learning algorithms applied in
573	selected studies.
574	Footer: KNN: K-Nearest Neighbors; LDA: Linear Discriminant Analysis; FNN:
575	Feedforward neural network; CNN: Convolutional Neural Networks.

Figure 4: Objectives and settings of AI/ML models. Panel A) displays the goals of
AI/ML models in rare neoplastic diseases (blue) and other rare diseases (orange). Panel
B) contains an upset plot showing the different combinations of features in the training
datasets of AI/ML models depending on the objective pursued.

580 Table

581	Table 1: Distinctive features	identified in the datasets	used for training the ML	models of included studies,	based on the specific goal being
-----	-------------------------------	----------------------------	--------------------------	-----------------------------	----------------------------------

Objective AI/ML algorithm	Type of instances	Distinctive dataset feature/s	Example of feature	Use cases (ref)
Stratification/Differential diagnosis	Patients	Genotype features	Burden value	[48–52]
Prognosis of patients	Patients	Genotype + Clinical features	Burden value + age	[53,54]
Variant/Gene prioritization	Genes/variants	Pathogenicity features	CADD score	[55–58]
Identification of digenic/biallelic combinations	Pair of genes/variants	Network features	Number of pathways shared	[59–61]
Identification of somatic mutations	Variants	Genotype + Sequence features	VAF + GC-content	[62–64]

582 pursued.

583 CADD: Combined Annotation Dependent Depletion; VAF: Variant allelic frequency

Identification of studies via databases and registers



Records removed before screening: Duplicate records removed (n = 113) Records marked as ineligible by automation tools (n = 0) Records removed for other reasons (n = 0)

Records excluded (n = 203)

Reports not retrieved (n = 0)

Reports excluded (n = 79): Not original article (n = 2) Not human (n = 2) Not ML approach (n = 12) Not original ML approach (n = 1) Not ML approach with genomic markers (n = 2) Not NGS method (n = 10) Not DNA-based NGS method (n = 19) Not applied to any disease (n = 18) Applied to disease but not rare (n = 11) Not diagnostic purposes (n = 2)



Reports not retrieved (n = 1)

Reports excluded:

Not applied to any disease (n = 1) Applied to synthetic samples (n = 1)





Α									B			
Rare neoplastic diseases	Differential diagnosis										4 .IS	-
	Somatic mutation identification											-
	Prognosis									Г	_ہ ت <u>ت</u>	
											lissue	
	Variant/Gene prioritization										Gene expression	
											Disease	
	Driver somatic mutations									SS	Alignment	
										ature	Clinical	
Other	Variant/Gene prioritization								I	ЦÜ	Phenotype	
diseases		-									Sequence region	
	Digenic/Biallelic combination										Network	
	5										Pathogenicity	
	Differential diagnosis										Genotype	
	j											1
		0	1	2	3	4	5	6				oals
				Numb	er of artic	les						ğ



- Differential diagnosis
- Prognosis
- Variant/Gene prioritization
- Digenic/Biallelic combination
- Driver somatic mutation
- Somatic mutation identification